A chronic disease still treated as a crisis
Despite being a well-characterised condition with clear clinical guidelines, severe asthma is still managed too often as a series of emergencies rather than a disease to be proactively controlled.2 Patients endure years of breathlessness, repeated exacerbations, and frequent emergency department visits before accessing optimal specialist care.2,8
Evidence now makes one thing clear: delays in care are costing lives, productivity, and public money — and they are largely preventable.
During this time, many are exposed to prolonged courses of oral corticosteroids — drugs that can be lifesaving in the short term but devastating when used chronically. The consequences are well documented: diabetes, hypertension, osteoporosis, cardiovascular events, and increased mortality risk.9 For patients, this means a life constrained by symptoms, anxiety, and side effects. For health systems, it means avoidable cost and escalating demand.3
Perhaps most concerning is that many patients come to accept this situation as inevitable. They stop expecting control.10 That resignation is not a clinical failure — it is a system failure.11
The case for earlier intervention
A growing body of evidence, reinforced by strong clinician consensus, shows that earlier intervention in severe asthma fundamentally alters outcomes. A recent multinational consensus among 500 healthcare professionals across five countries concluded that patients should move from referral to treatment review within 18 weeks — a clear, achievable benchmark that mirrors time-based standards already used in other chronic diseases.12
